.svg)
.svg){kind=small}
PITTSBURGH, PA -- The finch is in n@.
Solt DB, a public benefit company exploring the intersection of biology and finance, has been accepted into Ascender, one of Pittsburgh's early-stage startup incubators and ecosystems. The company successfully competed in the Ascender Bootcamp in April and May 2023. Incubation began on June 1, 2023 and runs through May 2024.
The year-long incubator program provides access to Ascender's co-working space in East Liberty (strategically close to disc golf), mentorship from experienced entrepreneurs and Carnegie Mellon University alumni, and guidance on strategic priorities unique to each business. Specifically, Solt DB will leverage the experience of the Ascender network to fine-tune the ramp of its overall platform.
New Website Launch
The launch of our new website (https://www.living.tech/) today introduces the beta of Solt DB's independent, data-informed platform covering the global bioeconomy. Our investment research helps individual investors identify attractive prices for biotech stocks in real time. We refined the idea for Solt DB Invest with an MVP that launched in May 2022.
Subscriptions to investment research ensure our platform has long-term sustainability. That strong foundation allows us to create value for the public benefit, even if you're not an investor.
The finch publishes free, objective analyses of the bioeconomy. We combine clear writing and data visualizations to make nerdy technical concepts accessible, so you can go beyond the headlines on a noisy internet. Subscriptions also allow us to self-fund the development of high quality, open source data assets such as the Solt DB Biotech Company Database. Our unique business model means our incentives are never tied to advertising, clickbait, or corporate sponsors.
The Solt DB Biotech Company Database features global companies across all biotech sectors, including companies that failed, went bankrupt, or were acquired. The database is annotated by domain experts and structured specifically for the bioeconomy, which allows it to be more accurate and granular than existing company or startup databases. It has been seeded with roughly 700 companies for launch and will expand each week as we validate additional batches of data. We estimate there are 10,000 companies to be captured.
As a data-informed platform, Solt DB combines data, context, and nuance to objectively discuss the challenges and opportunities within the global bioeconomy. We use a combination of data visualization tools within articles and as standalone content to make technical scientific concepts, sector trends, and financial information easier to grasp.
For example, this interactive data visualization shows how Ginkgo Bioworks' current active programs have evolved over time. You can hover over (or tap on mobile) columns to reveal data labels, view the source of the information, download the data, and more.
In addition to data-informed content, Solt DB today launches our newsletter (The Voyage) and Discord server.
Solt DB Invest has also undergone significant improvements based on feedback from early customers. Today marks the public launch of new features, including:
- The Margin of Safety Dashboard has moved to the web, enabling our bottom-up research to be quantified with real-time signals on the attractiveness of biotech stocks.
- The Live Demo allows anyone to see Solt DB Invest's complete research for 10x Genomics, Relay Therapeutics (our founder's largest position), and Selecta Biosciences without creating an account, giving us payment information, or handing over an email address.
- Solt DB Invest expects to expand its coverage ecosystem to 28 companies in 2024. This initial expansion of the stocks we cover includes AbCellera, Arrowhead Pharmaceuticals, Arvinas, Bolt Threads, Cognition Therapeutics, Day One Biopharmaceuticals, Ginkgo Bioworks, IGM Biosciences, LanzaTech, MoonLake Biotherapeutics, PacBio, Repligen, and Vericel.
- Solt DB Invest is also introducing Student Pricing. All student subscriptions will be eligible for Student Pricing for at least six (6) years. Individuals who graduate from Student Pricing starting in 2029 will receive a lifetime 33% discount to Solt DB Invest's standard pricing.
All individual investors who maintain an active subscription will lock-in their pricing tier for life and will never be exposed to pricing increases. To be transparent, we may require professional investors to upgrade to a premium tier in the future.
About Solt DB
Solt DB is a public benefit company exploring the business of biotech. The finch helps investors learn about science and scientists learn about business.
Subscriptions to investment research ensure our platform has long-term sustainability. That strong foundation allows us to create value for the public benefit.
The finch publishes free, objective analyses of the bioeconomy. We combine clear writing and data visualizations to make nerdy technical concepts accessible, so you can go beyond the headlines on a noisy internet. Subscriptions also allow us to self-fund the development of high quality, open source data assets such as the Solt DB Biotech Company Database. Our unique business model means our incentives are never tied to advertising, clickbait, or corporate sponsors.
As an additional show of our commitment to create public benefit, Solt DB donates 5% of subscription revenue to Nucleate Pittsburgh and 1% to Stripe Climate. Read more about our mission.
-cropped.svg)
.svg){kind=small}